News Are Makary's priority review vouchers about to be canned? Reports are emerging that the national priority voucher scheme launched by former FDA chief Marty Makary may be heading for the scrap heap.
News What do midterms mean for Trump's pharma and health agenda? As Democrats flip the Senate and House in a blue tsunami, we look at Trump's health and pharma policies that will likely see scrutiny and pushback.
News HHS doubles down on controversial peptides plan HHS unveils an enforcement holiday to manufacture of unapproved peptides - before the FDA decides if they should be allowed in compounded medicines.
News US Treasury proposes curbs on Chinese biotech deals China has emerged as a major source of drug candidates for pharma groups, but a new proposal by the US Treasury could slam the brakes on future deals.
News Despite US policy changes, drug prices stay stubbornly high US policy changes designed to curb drug prices seem ineffective, as the annual cost of new medicines still exceeds $250,000, curbing patient access.
News Compounded tirzepatide recalled after FDA warning A compounded version of Eli Lilly's injectable weight-loss and diabetes therapy tirzepatide has been recalled from sale due to sterility concerns.
News Isomorphic Labs raises $5bn in massive third round In yet another sign of the appetite for AI companies among investors, Isomorphic Labs has raised a whopping $5bn in a Series C financing.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.